What XBiotech does

XBiotech (NASDAQ: XBIT) is a clinical-stage biopharmaceutical company headquartered in Austin, Texas, founded in 2005 by John Simard to develop therapeutic antibodies derived directly from natural human immunity. Its True Human™ platform uses proprietary Super High Stringency Antibody Mining (SHSAM™) and genetic cloning technologies to identify rare, clinically relevant antibodies from blood donors — a position the company distinguishes from "humanized" or phage-display-derived antibodies — combined with a purpose-built, in-house single-use GMP bioreactor manufacturing facility (ISO Class 7/5 clean room) on a 48-acre Austin campus. The pipeline is centered on anti-IL-1α antibodies (vilamakitug in Phase II for axial spondyloarthritis; Natrunix in Phase II for rheumatoid arthritis and metastatic colorectal cancer via the TASKIN combination), plus Hutrukin (Phase I for stroke), Unmetix (anti-VZV + anti-IL-1α cocktail for shingles/PHN), and infectious-disease candidates targeting influenza, C. difficile, JC virus, and S. aureus.

XBiotech operates pre-commercially with no approved or marketed products. Revenue history is dominated by a single transformative transaction: the December 2019 sale of bermekimab to Janssen Biotech for $750 million in cash upfront plus up to $600 million in potential milestone payments, with XBiotech retaining anti-IL-1α rights for non-dermatological indications. Capital sources have included ~$250M cumulative funding (seed through IPO), with the 2015 NASDAQ IPO via Dutch auction raising ~$76M and ongoing reliance on Swiss investor rounds and insider/major shareholder support (≥27% insider ownership). The company is funded to advance multiple Phase II programs but continues to report significant operating losses (most recently $0.88/share quarterly loss). Leadership transitioned in 2024–2025 from founder-CEO Simard to Interim CEO Sushma Shivaswamy, the former CSO. Future monetization depends on clinical readouts across vilamakitug, Natrunix, Hutrukin, and Unmetix, and on the ability to retain rights and build or partner a commercial launch capability in rheumatology, neurology, and infectious diseases.

Name

XBiotech

Legal name

XBiotech USA, Inc.

Website

https://xbiotech.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

XBiotech is a clinical-stage biopharmaceutical company (NASDAQ: XBIT) developing True Human™ antibody therapies derived from natural donor immunity, with in-house GMP manufacturing and a pipeline spanning oncology, rheumatology, neurology, and infectious diseases. The company is pre-commercial with no approved products, funded historically by a $750M bermekimab sale to Janssen (2019) and a 2015 NASDAQ IPO.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutic Antibodies

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

Keywords

• Therapeutic antibody development
• Biopharmaceutical drug development
• Monoclonal antibody therapies
• Clinical stage biotechnology
• Anti inflammatory biologics

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Licensing and Acquisition Revenue: XBiotech sold bermekimab (its IL-1α blocking True Human antibody) to Janssen in December 2019 for $750 million in upfront cash plus up to $600 million in potential milestone payments. As part of the agreement, XBiotech retained rights to develop True Human antibodies targeting IL-1α for non-dermatological indications.
2. Therapeutic Antibody Development and Commercialization: Pre-commercial stage biopharmaceutical company developing a pipeline of True Human antibody therapeutic candidates. Revenue will be generated through eventual product sales following regulatory approval across multiple therapeutic areas including oncology, rheumatology, neurology, and infectious diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

XBiotech is a clinical-stage biopharmaceutical company that discovers, develops, and manufactures True Human™ monoclonal antibody therapies derived directly from natural human immunity rather than animal-derived or engineered sources. Its pipeline spans anti-inflammatory antibodies (anti-IL-1α) for oncology, rheumatology, and neurology indications, as well as infectious disease antibody candidates targeting shingles, C. difficile, influenza, S. aureus, and JC virus. The company operates fully integrated capabilities, including its proprietary SHSAM™ antibody mining platform, genetic cloning technology, and an in-house GMP manufacturing facility in Austin, Texas.

Product overview

XBiotech is a fully integrated biopharmaceutical company developing True Human™ antibody therapies—a portfolio of distinct monoclonal antibody product candidates derived from natural human immunity rather than animal or engineered sources. The core platform combines Super High Stringency Antibody Mining (SHSAM™) technology with proprietary genetic cloning and an in-house GMP manufacturing platform. Key products include: vilamakitug (Phase II for axial spondyloarthritis), Natrunix (Phase II for rheumatoid arthritis), Hutrukin (Phase I for stroke), Unmetix (IND-stage for shingles), Bermekimab (sold to Janssen), plus infectious disease candidates targeting influenza, C. difficile, JC virus, and S. aureus. The company operates its own manufacturing facilities in Austin, Texas.

Differentiator

Problem solved

Functional benefit

Brands

• True Human™: XBiotech's proprietary antibody discovery and development platform that derives therapeutic antibodies from natural human immunity
• Natrunix™
• Unmetix™
• Hutrukin™
• Natrunix™ Trifluridine/Tipiracil (TASKIN)

Products and services

• Natrunix True Human anti-IL-1α antibody candidate for rheumatoid arthritis that blocks interleukin-1α activity to reduce joint inflammation, tissue destruction, and pain; Phase II clinical study completed.
• Vilamakitug (PT064) Next-generation True Human anti-IL-1α antibody in Phase II development for active axial spondyloarthritis (V-SPINE trial); derived from donors with natural human immunity and administered at 400mg via 16 weekly subcutaneous injections.
• Hutrukin True Human antibody candidate intended to reduce brain injury after stroke by limiting reperfusion injury when administered prior to clot-busting procedures; Phase I study completed.
• Unmetix™ Combination antibody therapy (XB22-14 + XB2001/vilamakitug) for shingles and post-herpetic neuralgia; non-clinical data completed and IND submission planned.
• XB22-14 True Human neutralizing antibody targeting varicella zoster virus, isolated from healthy donors with natural immunity; component of the Unmetix shingles therapy.
• C. difficile Therapeutic Antibody First-of-its-kind oral True Human antibody therapy for C. difficile intestinal infections that blocks bacterial motility and adhesion; manufacturing process development underway for oral delivery to the intestine.
• Influenza Antibody Candidates (IH201, IH302) True Human antibodies identified from genetic analysis of over a century of influenza viruses, capable of neutralizing all known influenza strains including the 1918 pandemic strain; master and working cell banks established.
• JC Virus Antibody True Human therapeutic candidate targeting JC virus, a human polyomavirus that causes progressive multifocal leukoencephalopathy (PML); donor antibody screening underway.
• Omodenbamab True Human antibody targeting S. aureus bacteremia that neutralizes bacteria including drug-resistant forms by reversing immune evasion mechanisms.
• Natrunix™ TASKIN Study Phase I/II clinical study combining Natrunix (1000mg) with trifluridine/tipiracil (FTD/TPI) and bevacizumab for metastatic colorectal cancer (mCRC); Phase II portion ongoing.
• True Human™ Antibody Platform Proprietary technology platform for discovering and developing therapeutic antibodies directly from natural human immunity, using SHSAM™ technology to identify rare, therapeutically relevant antibodies from blood donor samples.
• GMP Manufacturing Platform Fully integrated start-to-finish monoclonal antibody manufacturing platform at the Austin, Texas facility with single-use systems covering production cell banks through aseptic fill of vials and pre-filled syringes; clean rooms meet ISO 14644-1:2015 Class 7 and Class 5 standards.

Quantifiable outcome

• Bermekimab acquired by Janssen for $750 million upfront plus up to $600M in milestones (2019)
• +4 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core, flagship and minor.

• University of Texas at AustincoreStrategic or Co-development Partner · 1 February 2026Ongoing collaboration with UT Austin applying advanced microscopy imaging techniques to advance infectious disease pipeline. Publication in Journal of Microscopy (DOI: 10.1111/jmi.70038) highlighting work on C. difficile biofilms.
• BioBridge GlobalcoreStrategic or Co-development Partner · 1 January 2020Collaboration with BioBridge Global (BBG), a major Texas blood bank, to analyze blood samples for COVID antibodies. BBG provided convalescent blood donations to XBiotech for development of True Human antibody therapeutics against COVID-19.
• Janssen Biotech (Johnson & Johnson)flagshipOEM/ Whitelabel/ Licensing Partner · 1 December 2019In December 2019, Janssen acquired bermekimab from XBiotech for $750 million in upfront cash plus up to $600 million in potential milestone payments. XBiotech retained rights to develop next-generation anti-IL-1α antibodies for non-dermatological indications. This was the largest biotech acquisition deal involving a Texas-based company at the time.
• Dr. Daniel VasellaminorStrategic or Co-development Partner · 1 January 2015Former CEO of Novartis joined XBiotech's board of directors. Named 'most Influential European Business Leader of the Last 25 Years' by Financial Times.

Scale indicators6 records

Recent moves9 records

Expansion highlights7 records

Market position

Strengths4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/XBiotech_USA
• Facebookfacebook.com/xbiotech
• LinkedInlinkedin.com/company/xbiotech-usa-inc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XBiotech